Khona Scientific and Bright Path Launched Project bioFORxGE
The companies have partnered to establish domestic end-to-end production of essential taxane-based medicines.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Should the U.S. prioritize domestic manufacturing to secure the supply of essential medicines?
Khona Scientific and Bright Path have joined forces for Project bioFORxGE to create a domestic supply chain for critical taxane-based drugs. This initiative integrates biosynthetic production with advanced chemical manufacturing to secure the U.S. supply of these medicines.
Why it matters
The collaboration aims to address long-standing vulnerabilities in the pharmaceutical supply chain by reducing reliance on external sources for critical medicine production.
Project bioFORxGE combines biosynthetic Key Starting Material production with continuous-flow chemisynthesis. The process utilizes Khona Scientific's BiDS platform to derive 10-DAB from renewable domestic sugar feedstocks.
The players
Khona Scientific
This biotechnology firm specializes in platform technologies that enable the biosynthesis of essential chemical precursors.
Bright Path
This organization focuses on advanced reactor technologies used to optimize complex chemical manufacturing processes.
The details
The project centers on the production of the API Paclitaxel, with plans to expand manufacturing to include docetaxel and cabazitaxel. By integrating biosynthetic KSM precursors with Bright Path's STT reactor technology, the companies aim to transition directly from sugar to finished injectable drug products.
Timeline
The partnership and the launch of Project bioFORxGE were officially announced on October 13, 2026.
The Tech Race
This project marks a significant effort to shift the domestic pharmaceutical manufacturing supply chain toward end-to-end local production. It moves the industry away from legacy dependency on imported precursors, positioning the companies to secure critical drug availability through integrated automation.
Residents in Boulder and throughout the United States may eventually see increased reliability in the availability of essential cancer treatments. This technological integration aims to stabilize drug supply, potentially reducing the risk of shortages for patients requiring taxane-based medicines.
The takeaway
This collaboration signals a shift toward local, renewable-based chemical production for life-saving pharmaceuticals. The focus on domestic manufacturing could set a new precedent for how healthcare providers source critical injectable drug products.
Further reading
For more information on current industry developments, visit Biotech.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the U.S. prioritize domestic manufacturing to secure the supply of essential medicines?
